ATAI - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome the ATAI Life Sciences Second Quarter 2021 Financial Results and Corporate Update Conference Call. Currently all participants are in listen only mode. This call is being webcast live via the news and events section of the company's website at www.atai.life and is being recorded.

For opening remarks I would like to introduce Greg Weaver, Chief Financial Officer of ATAI Life Sciences. Please go ahead.

Greg Weaver

morning. good and you Thank Welcome to results Life financial XXXX second corporate update quarter and ATAI conference Sciences our call. www.atai.life of The press the website on section in the June today XXth is results quarterly XXXX at Form-XXQ our will ended release reporting investors our and financial and report our with file available SEC. media

and Dr. Co-Founder and our me are Brand, Florian Rao, Chairman. today and our Scientific Srinivas Christian Officer; Joining Founder co-founder and CEO. Angermayer, Chief

statements Litigation we'll that by call, making of be be provisions forward looking XXXX. intended today's covered are During the of certain to the Reform Harbor Safe Private Securities Act

uncertainties While and could to results materially management's performance current actual cause represent from these today, differ those of of and the ties statements to projections that results, as subject results actual about future are expectations. expectations risks many

addition statements these June prospectus described the XXXX. the our Commission, any are that XX risks our including subject Securities filings In highlighted are during SEC on risks with with the made Exchange in various call, of to and filed to final

disclaims required on applicable And caution speak ATAI's management's now and forward place the over be Florian to turn as undue call these not change. obligation any XXXX to such CEO as update statements, reliance XX even Florian. may of looking only statements ATAI today, Your law, to views August except which by if like to Brand,

Florian Brand

call, our in earnings million. joining Good June, $XXX for raised pulling successful morning, we completed everyone. you Thank in where first our IPO NASDAQ all

decentralized we intend to these thrilled in the mission enthusiastic community. We continue drug And from two platform proceeds by ways. to our use development the are advancing our response to investor

we to mental pleasure on me heal and so co-founder to existing become by Board and life. leading that everywhere executing approach, objectives by development to we patients transforming gives the second, visionary in you everyone, Chairman, more programs, of incubate, drug introduce with the treatments unique health the can Angermayer, will mental great With on disorders live new by to ultimate and our to Christian pipeline, it enabling technologies. and Christian? advancing health, fulfilled now, company and do my First, aim focused acquire our a so invest our continuing And

Christian Angermayer

part commitment you want and team, this Thank to solutions co With share my treatment mental discuss of including as In own entire that health is most common it single founders important of my but to of to disorders and in context, started ATAI transforming few first This everything a everyone. life. aim significant offered the not was experience. I'm psychedelic ATAI. with I in approaches, take team, moments the my also compounds. ATAI's know, to by short, of I experience many exploring psychedelic and myself. experience in my investment ATAI And emphasize only unconventional entire the a you meaningful the the made founding origin

will the psychedelics of and I this disorders. from come. appreciation future in ATAI's basis depression, desire progress and both real friend invest with and suiciding from therapy. to for potential therapeutic researching I with to call mental hope a you what leave for hope brighter an health date even be Those sound Las our [ph], [ph] healing my from treatment greatly heavily addition, suffered who In systemic rigorously experiences Welder Co-Founder, my to

stigmatized help of solve biggest on Srinivas details that I the one issues mental While is milestones, is our PTSD, leave unofficial official aiming me topic. in More healthcare, diseases. to ATAI most significant health it most chiefs what still as to and emphasize And anxiety, than health to intractable to X people mental higher, one Florian the likely proud. a number. from is elaborate mental suffer of addiction, globally the I billion problems just and depression, health want makes other disorders. are The unfortunately,

young have in a built XX company industry, psychedelics have our and funded more than to well programs. We the continue $XXX advancing million

development programs and a over they're to pipeline, rich add more aiming time. We business have

All ones, pipeline, evidence and which has of R&D drugs, for the catalysts indication psychedelic next strengthen prior with months. our continuous approach the non of the ones, expect news portfolio and the both over of XX Because helps humans, our psychedelic outcome trials. XX our flow the in extensive our we

more while goal. big three. this that strive through just illustrates assets mental keep psychedelics, step leading funded phase that to for to know, Our to of interest well pharma health value In partnership that first and other our we building while company stakeholders. as We control at shareholders convinced you very I'm we is our short, potential and believe with become globally, Otsuka the possible. achieve And in the pharma are partnerships are highest

Greg Let business. our me additional Florian, Srinivas will now CFO, hand together on it our back CSO, updates with and to who provide our CEO,

Florian Brand

me health comments. to to Allow briefly a me Sciences. few that we with Then mental members Christian. family ourselves years the firsthand you, followed disorders. with provide significant our company, quarterly as not and three development Srinivas you now the reports our financial the ATAI overview and ago familiar Greg let founded a yet give by introductory from Life highlights an review People will witnessed Thank unmet will pipeline, We of provide from drug ATAI suffering friends response need Q&A.

these our companies. therapeutics. companies utilize operate digital we enabling of decentralized or in in such significant controlling to a de either are accelerate we technologies, in acquired, or know, interest support model as business incubated all development allows and us novo. and the have This our you And As compounds

selection diversified. Process with approach allocation. binary health we also success. that and Combined innovative developing humans. risk, incorporates discipline which based approach, capital opportunities is the to compounds a focused differentiated be are in with portfolio can and milestone designed the at pipeline unique both level, is on evidence clinical program ATAI mental our prior We to aimed increasing have avoid focused On process on a asset of an probability

therapies. have on significant example to mental an of several that our focused Otsuka target Outside only in current of least mental business by of a pharma. world of year deal opportunity potential once of health in technologies. psychedelics, deal we and maximize potential We for $XX years, indications One in of XXXX. our by represents programs, large billion we market class in of industry have value. We XX indications capture indication ability perception organizations optimize expansion, We our partnership compounds three and In approved. demonstrated this intend to value believe developing a licensing first is build the health. with pipeline with additional company sales an between major developments, focus six promising each X billion partnering our around This biopharmaceutical at enabling innovative market invest and of already other our this shareholder annual leader aggressively untapped with most see estimated to portfolio opportunities these a indications

it highlight flow. the is our news to important Looking density of forward,

that initiated of the QX the in study Sciences are and XB of have two months extensive catalysts to X XX pipeline. We is portfolio trial Life have expected provide top data phase XX this year. second and a end upcoming phase R&D to imminent their our that over the The approach compass on expect pathways results first milestones has of the most year, next our Recognify and line result by

plan for perceptions DemeRx still we this OUD addition, and quarter. TRD phase phase In initiate trial to two in X,X trial

mental we pipeline. Additionally, we call position, a are to disorders. now health well entire trials and trials maintain and next very for strong over the to With on phase a cash plan more year. update initiate leadership our to Srinivas three X for X will for detailed turn treatments I phase the developing equipped

Srinivas Rao

Florian. Thanks,

term broad milestones with nearing we visibility perception with the a As assets On have array highlighted, the clinic. call, are most on exciting I and the highlight upcoming neuroscience. far programs will of starting as this focus in near

compound for is lead XXX of academy. So PCN our a formulation perception

provato acting Our lower are potential [ph], compared treatment IVR as at seven ketamine depression home may demonstrated Academy as contrast rapid properties the administered developed This subject ketamine with ketamine. marketed In be with in supported must and which the in resistant using doses, contrast modulators is results and non-dissociated preclinical has our the at hypothesis ketamine an in our for efficacious published abuse glutamatergic sub higher use. patients to only clinic. open as trial in potential TRD label durability antidepressant or of ketamine models, recently as be The is dissociative a ketamine. being greater that as potency,

serious home. perspective before, mentioned differentiation, commercial from to particularly delivered up in doses XXX we've IV. and safety about potential product well a adverse and the subjects perception X the announced the a In scalability aspects positive were there of we're February XXXX, As results tolerability potential PCNXXX compound effects The for tolerated, of treated no reported. these XX and at phase of milligrams demonstrating excited was

Additionally, were that pharmacokinetics to compared and proportional. ketamine. of higher study be required the approximately PCNXXX demonstrated does perceptual PCNXXX changes to the to found doses as Notably, induce plasma substantially

to XX Importantly, a will an conducted to PCNXXX XXXX. that we we the use. our a to IV phase anticipate initiating testing XX home anticipate bridge formulation we believe Europe in will randomized controlled blind patients at We ketamine conclude of TRD. parallel, of enroll across double PCNXXX formulation study sites diagnosed QX to of our XXXX. IV two be phase In bioequivalence running trial This the intend late aims and through in of with placebo formulation of study subcutaneous trial X from support

Sciences previous a approved RL-XXX glutamatergic a is pro-cognitive alter schizophrenia based the challenge to commence development are April pharmacology patient's More Life impairments quantitative XA of in in of is as mechanism electroencephalogram, scopolamine are healthy on clearance the XXXX, aggregate significant orally to an Recognify safety, modulator. for effects proof start this The RL-XXX though or for the XX this of evaluate the which clinical compound receiving the US face objective with for a developing for Recognify study complex of is GABA-B associated We're the CIAS. volunteers. of initiated drug is indication exploratory as a IND produce measures therapies and treatment cognition. cholinergic, to QEG available biomarkers from presently treatment the brain Next of to cognitive balance CIAS viewed involving receptor need, unmet the condition. is with FDA study specifically, or challenging RL-XXX the In that extend excitatory/inhibitory tolerability, results effects. for study developing In RL-XXX and trial to designed after

to a shift Ultimately, observed task. and several in on comprehensive we're a frequency into are the looking with when which resulted progress XA data line spectral of including cognitive top PXXX, to in anticipated beta pro much traditional the a memory, on potential frequency of verbal higher on matrix Further, theta us focused evoked to band confidently of RL-XXX the improvements all QEF we're auditory trial controlled effects lower alpha effects addition in to year from it end oscillations. placebo in cohorts RL-XXX administration In face latter will measures, of including to will and analyzed. consistent this the proof investigating oddball a response endpoints, for Such latter the battery. subsets data an negativity allow double are the study. be The concept trials by the blind more cognitive band

rapid band. been Based have in or etifoxine, an anxiety in mechanism dosing treatments of approved GRX-XXX single which with June phase associated with looking lower development prescription increase we an of XXXX, healthy Further The risks a will including data oral database, Australia, countries thought therapeutics abuse intended upon an approximately anxiety. treating looking power postpartum one compounds. deuterated a sending IV to anxiolytic underlie a depression. related adults. GRX-XXX, current that activity similar found use This XXXX was States a target of have the IV for in biomarker the with disorders. less a treatment increased qEEG. sending safety will class mechanism has spectral ultimately our been of viewers we compared action hypothesized changes etifoxine GRX-XXX GRX-XXX. XX GRX-XXX well greatly provide the or for activity tolerability as the qEEG formulation version in as the trial as improved XXXX. pregnemon dose A in onset Next has blind dose enable and demonstrated and to we the compound is is we're at but the is in action etifoxine is doses of extensive that randomized will rapid the data believe pregnenolone, frequent double Top placebo beta noted without And etifoxine. to of etifoxine United with engagement cognitive for relative with a which then which the observed sedation, initiated France for and of in and enroll formulation compounds. this multiple, of future Like And benzodiazepines, anxiolytic for of that of that another using In the using [ph] X controlled to we're trial Such X etifoxine, program also history GABA is line neurosteroids, conducted. tolerability, GRX-XXX A phase impairment, Mechanistically deuteration a production of expected early long GRX-XXX we safety the pharmacokinetics etifoxine trial primary pharmacodynamics to XXXX design, latter phase of are of independence study

DemeRx IB. to Moving

commence recently studies quarter and trial results and medicines from and in to designed developing end, psychedelic product the use UK disorder. naturally tolerability, UK We received an in ibogaine, a component the disease in the phase pharmacokinetics are subjects users in that efficacy, opioid disorder. recreational is of the one assess treatment healthcare formulation DMX-XXXX patients products oral to potential phase or will agency X/Xa drug for occurring and an X/Xa To third of safety, opioid future a volunteers DMX-XXXX anticipate healthy XXXX. phase regulatory inform of is enrollment. as modifying with we We the The approval of use initiating MHRA exploratory

obtain expect X of We XXXX. in the phase safety data early this element to from trial

extensive rolling acceptability [X:XX:XX] we that phase associated the approach an San update therapeutics the and testing technology it noted in at in two introspect deeper entering year. clinic have Diego. pipeline will should introspect early trials milestones the out our stage next next and starting X that and provide will these be Academy We clinic be undergoing being a anticipate [X:XX:XX] currently phase user Further, in developed digital XXXX are programs as year. at We on trials

double investigating in mention Finally, developed antidepressant We a of dosing in psilocybin trial trial Getting be of a dose a blind patients XXXX This X-HTXA-R largest this psilocybin, compound of the an industry of is a year. clinical funded rapid-acting this synthetic this will Greg for efficacy our financial safety phase ranging to psilocybin the and COMPXXX COMPASS team Xb completion their compass is announced in trial is brief diagnosed line XXX commended total trial the order. of a agonist now work. study top the incredible later oral, clinical as data COMPXXX, achievement, COMPASS is conducted to today. stage the formulation this look of of turn for highlights. overview call should and of in and In forward to over or I Pathways: the with TRD. randomized its which major an being proprietary June

Greg Weaver

and Srinivas hello, everyone. you Thank

in $XX first issuances. expenses revenue sale million series of million convertible the investments and million of net compared shoe and $XXX.X raising IPO in cash in As completed of gross of in and million common million in green full C $XX.X investments Cash or XXXX. million we proceeds companies months The to million $XXX.X proceeds as $X including XX, to from XXXX. XX D the of $XX notes, of proceeds of million our series from attributable total XX.XX June, is platform June six half proceeds December $XXX equivalents million of increase shares, stock operating offsetting net payments plus mentioned million $XXX.X the conversion of $XX.X of and IPO upsized $XXX.X the Florian licensed for as of million exercise.

pharmaceuticals. to of The million CRO million investments for first stock to $XX.X expense, million use related was million months and costs, XX same the the we And million to programs. were positive process $XX advancements licensing operating and million from our Our R&D of for compensation personnel respectively relating the the of cash periods. expenses Otsuka and $X June and million $XX ended increase of million to half expenses of ended and in follows. were $XX.X the our proceeds R&D three XX of XXXX million six Operating and also license attributable in with record in Neuronasal as including the prior includes an as $XX.X agreement and June costs $XX.X based and million year for three months acquisition XX perceptions revenue compared $X six increased in six in InnarisBio. $X effect expense of $X.X expenses months the for collaboration received XXXX, and and development ending June 'XX Research which

ended the a $XX.X was $XX.X was G&A modeling. portion recognition expense IPO periods. vesting was the and ended prior $X conditions. comparable of to for $XX.X $X.X six XX the same million months Moving performance $XX,XXX XXXX year-to-date of the to G&A $X.X million related compensation million professional to the expense prior based respectively, for $XX,XXX million personnel Total for $XX.X and related based and months public conference portion support and and and This expense, compared requirements. of and stock other fees, million the million three stock to were million costs, year achievement growth were as June reflects based to million periods, attributable The expenses R&D year increases for and compared partial platform June three and as including in XX your the million $XX.X $XX.X to and six respectively, company costs our $XX.X

Srinivas Rao

in half to your onetime attention first our results. items draw like I'd two, to

in participated $XX.X of ATAI round. of million booked of Pathways. the XX.X% equity may follow In on we $XX.X licensing intent and at to our Otsuka is And revenue quarter call and recorded back management to the at million gain the on million from relating perception First hand point collaboration this XXX,XXX campus. the strategic own investment licensing ATAI with $X we in drive purchased compliment agreement shares the for Florian. out COMPASS And COMPASS the also I'll dilutive now perceptions deal. to with team now the and additional transactions future. everyone pharmaceuticals. I involved non licensing second that

Florian Brand

investors year. as well supportive ATAI Thank you, the all would thank we've entire Greg this to and I achieved to Srinivas. our their like as contributions team team in

in important with on catalyst readouts, in and continue our are clinical XXXX ahead, advance. incredibly energized drive and to they updates as program for to provide initiations an Looking is development. time reach trial an we we exciting will ATAI and XXXX additional This business

health. structured Before by X incubating that, like as our and happy enabling and we humans, our in prior I broad phase date, our basically drug to five, in attraction on balance compounds large development end mental has our data drug forward. by into The the will a three accelerating take our to we and following ATAI would elements. and biopharma is With takeaways only combination we through leadership developing strong solidified by complimentary model are within technologies. with XX to company unique key the probability been acquiring the capital with and company Number pathways. one, an developing drug compounds Number have questions, portfolio to highlight COMPASS evidence roadmap progress of are including position design, pharma. to we near year the the developer five with on focus allocation. collaboration sheet psychedelic Number in four, based investing Number development innovative two, maximize Recognify drive activities success development date with where readouts has to portfolio, approach, validated questions. from of our and entered approach by catalysts, that term business has a we continue take to three, differentiated momentum our milestone Number

Operator

the Our question. with line Duncan your Charles of with first comes from Please Cantor question Instructions] Fitzgerald. [Operator proceed

Charles Duncan

and Florian morning, good Yes, team.

and of XX. the all, And thanks and the for question. month outlining Call First the it for plan. week XX taking details thanks all

quick on perhaps a could regard as symptom provide question more Xa and regarding presentation, steps [X:XX:XX]. well with I I'm bit for and concomitant the guess if result as study duration. detail medications phase So you call frame to and next a RL-XXX it I informing out a had criteria dosing wondering enrollment the useful of little on that

Florian Brand

Absolutely, the for Charles, question. and thanks

allowed know, one to the mean, speaking, have And meet as a normal. possible. related it, about limiting That of I compound. You concomitant they're other we one and, meds, [X:XX:XX], top sigma of generally schizophrenia they to that it are homogeneous, And population with criteria below impairment. in our just terms to cognitive to believe, have course, keep of as I that's the is, and as really

outcome, as I X mean, recall, scopolamine previous In a study. to terms challenge of they trying study, the things. is of a And trial, here the do which you'll what meaningful Phase two results that extend we're found is in

tend alterations found also generally First, particularly have specifically, And frequencies. in and higher speaking, lower and associated shifting pre profile, really of higher cognition. they it from found was post those do memory. frequencies. verbal And quantitative frequencies frequencies are degree schizophrenia, improvements spectral to lower drug cognitive in they on with to changes improved found the with impairments, they prominent run they concomitantly Folks suppression such of at frequencies with qEEG, that, some with higher

So a the looking is the spectral that of first very replication we're at thing shift. quantitative qEEG

evoked well. that, a much, we course, study, very we some a one is would And, Obviously, kind expecting the we'd assessments great. like be extend the of from be of to Obviously, with aren't be concordance to big measures of some are then know, we if speaking, to proportionality looking going I mismatch thing and but cognitive a then doing key of potential and but well. and as mean, improvements PXXX. we're broadly find shifts, the negativity there that small you win would that's qEEG as concomitant, the be here. of potentials shift. spectral this first at some around would That's So the evoked

Charles Duncan

then pipeline additional one quick up follow you thank for Okay, question, a Greg.

about as come XXX out call term is spoken but that comp that represents the of of it date, new largest this well towards to and on COMPASS silicided could end year, given to current of in effect as the paradigm management terms you'd like trial this, to like perspective the Regarding hear your see results to we'd clearly we've what durability, three this the trial and longer week sizes of relative it controlled response a that rates, of the to standard care. given

Florian Brand

one Okay, to Charles, With to Greg, I'm if I of said, chime endpoint some well key, primary three as things is to of course, do is, think certainly that you please rapidity but shows the onset, want mean, degree of course, willing we're you as looking the I a Greg, take respect study, at that, weeks their in, clearly, durability. of of the that so. psilocybin that

of an remission. with part of duration someone efficacy is the course, as the Of promise, promise [X:XX:XX] into of extended driving I mean,

certainly to over results that this these obviously, subsequent emission inform studies. this going clearly, endpoint data does watching we certainly out looking the on for obviously that. weeks to And be we're subsequent right, so from the question? powered really of key interpreting such It's Does quite trial. go there and for the responder the As will will trial three data out, primary mean, be answer at to I from weeks. at your course, XX weeks data understanding

Charles Duncan

was it six year? over the for My for looking to a this OpEx, for to you. relative really courses see it you follow does. but statement course over XX the And up say How how guidance, yes, Yes, months, do next say range. of do just was you Greg the income not

Greg Weaver

first more in half process cash stage, I activity running personnel see R&D the internally. Greg quarter. out the got some growing costs half moves you to the clinical some Charles, the likely out, in inside spend companies to and here. platform you've capabilities Good pipeline as it about we'll well. as And support So was question. But in OpEx have XX support the thanks, going and to there non first additional that the we're Because to a we think continue grow spike the a numbers, build [X:XX:XX]. to as R&D strip And

As Maybe directionally range a we north now. we range of XX per forward, to quarter a okay. you as XX of know, are go would be where it'll be

Charles Duncan

Okay. taking sense. you Thank That makes for questions. my

Operator

proceed comes Baral question of your next question. line Cowen. from with Our the Please Ritu with

Ritu Baral

XXXX, as as when data And for most what to got we QX? looking we the in do S versus get dissociation Good the start one. in questions in be My I treatment is of to the and that duration guess depression that but Can ketamine, Thanks paradigm X you plan us on first using up. should dosing and and scales morning, are one question. that phase preview the you're on for important the perception and taking degree efficacy, well I've you then the dose upcoming guys. that way for follow the a

Florian Brand

No problem. with start then. one, I'll that

and dosing, on the some on that results. sub based can in that, have doses point. X, X dissociated, we going guided say dosing, So is latitude on based haven't certainly this with phase that are the we are we really I at of terms phase What on

essentially So we're doing what that's there.

obviously, In here. going the of [X:XX:XX] endpoints, kind of is terms key be to

about those talked also in You frequency.

this trial it's So what a IV of following of compound there. the a is of that single dose and clearly single administration we're results a

preclinical of dosing we hours or do unlike results will anticipate some of durability re There's which data greater The frequency XX us frequency dosing other symptomatology days of the S ketamine suggesting will give proper. indication at studies. this required trial consistent XX primaries the So a the here. you Not of be know, as ketamine or with depressive ketamine effect.

be able hypothesis is driving S than of course, for a that might we ketamine really frequently this that's which, So weeks. what's dose four to week twice less

dosing know, of terms the and the is a long so it kind here. endpoint of obviously, So endpoints. key [X:XX:XX] that's you in in of terms short of

not for one terms psychedelic the there's here. we granularity dissociative/psychedelic give we're that the five is best I'd what doing lot type certainly And And is really this. seeing [ph] suited sort including that widely the we're Obviously, perhaps are of effects, us kads that, in that's effects the something say In more used industry. things two that focused the on. a compound. DSC will the on that We're of also may [X:XX:XX]

Ritu Baral

study And the you're is or DemeRx in question Phase next QX. it. then starting X/X planning Got my that on

study? the cardiovascular when? So, could any special monitoring users, out and doing IV since you in you around is recreational what efficacy sort again, [ph], mentioned safety of of PK glean are data drug it you this the And

Florian Brand

signal Yes, for of is in data. There so are in depending population, with some I done. had QX there wasn't compounds multiple that this terms publication of clear. the necessarily experiments been on cardiovascular were certainly I The [ph] existing safety, a course, of concentration prolongation dosing Ibogaine mean, there think

that's that looking we're closely. at something So very

doing are that if a endpoints well doing there's like QX of dose repeated relatively as ECG standard We we're prolongation. and fashion course, is sort range here. or [X:XX:XX] to that would can of we to of get We see, [ph] devoid

here. So the that's really focus

In medically efficacy piece really are focus on the mean element, is those endpoints undergoing assisted detox. X the terms the efficacy in basically, the which one and that phase are of I phase individuals

you component their withdrawal, at there, than will, what X remission, focusing trial. phase So, within and is rather at we're term long the know, if on looking really the then you of looking

Ritu Baral

Got it. Thanks the questions. taking for

Operator

with question next RBC with question. Abrahams your Markets. Please the Brian Our comes Capital of line from proceed

Brian Abrahams

progress. the was the status and you of on with thank my taking guys, if the about all Maybe congrats for talk could subcutaneous just much starting I PCN-XXX. wondering you Hey, formulation. so questions

be a would moving study You comments. mentioned in your opening into bridging that

that starting I volume factors, would be guess that study where What administration? two if there for your that gating Just wondering, any stands? what and are target

Florian Brand

the details that mean under is the the formulation of of injector. is here of then that lot know development. and there's I long compatibility are to formulation it a and subcutaneous you the device public. course, short think the And not itself with I

results. basically roughly looking And all relatively it's the opening you're IV get quick, study, are I So the subcutaneous. ongoing, remarks, work right? very [ph] the X data straightforward, is the and comparative familiar, that we as we with to that is from in as contemporaneously, mean, BE mentioned phase versus

ongoing currently. that's So

two keep here it what two obviously, our that's terms milliliters. with And standard of it the subcutaneous we're under volume, we'd formulation. pursuing significantly In to obviously like And is for is volume keeping milliliters. under

Brian Abrahams

have recently guess. Great, thanks. questions And I you couple [X:XX:XX] just a also announced there. then of

might on that therapeutic guess, you with I'm to could and bit about an vision X-HTXA advantage. element interact administration provide in that pointed opening don't monitoring your remarks your I to curious the that secondarily, which then, First little digital and with of dosing assist there, which there's integrating potentially additivity, a how help all, you therapy out you talked for enable, also SSRI. And

TRD your to I'm as curious how if Thanks. other you terms could in combination in speak So envision with both as well potential, programs you with SSRIs also program the future of pipeline?

Florian Brand

well. point. Yes, ketamine of really experience compound mean, the that's with It properties psychedelic with well as Salvinorin I the terms I that that's clearly, with the has many classical some think key aspects that psychedelics, overlap is psychedelic. as of in as

tend but dysphoric. in little antidepressant some related efficacy, it's they that, things of certainly curious a like compounds around be very Kappa be while to overall, side, interesting this pharmacology, more such very to agonist. a to Kappa the that data tend more case, form partial are they agonist Many on more agonists and So [X:XX:XX] anecdotal

there's So potential with of opioid this used the exists et quite really And compound. SSRIs, concurrently be to an certainly cetera. is SNRIs, because its interesting receptor, pharmacology

as here, that's aspects to depression underlying is in broadly pathophysiology that kind clearly really including, patient keen So something substance different that's have More multifactorial may certainly value we've dysfunction. really what populations opioid different obviously and driving and of very of we're that what the discussed, out pursue.

population. So that to this suited better perhaps is

pursuing interested that's and certainly compound this we're why it. So in that's,

digital of this is I therapeutics, point. obviously, somewhat broader a terms mean, In

several mentioned is vary the You the know, we've from to going not undoubtedly that times outset and it's patient. readouts frequency by clear necessarily

support There'll So, compound and work you in course, subsets be psychedelic psychosocial a only then subset remission. post, the both pre don't a and be term has regardless of administration, setting patient, pre to terms expectation digital providing that a of psychedelic, that the we long and envisioned pre know, therapeutics there'll of very the respond. not psychedelic the post And dose. with looking something again, physician well you as to as And at giving Does more we're as is broad. others. [X:XX:XX] preparatory physician re therapy also your not that as know, tracking [X:XX:XX] CMT be patient input this the And, symptoms. radio question? well unlike should certainly with the program the treating a when program answer is but the as reset This that

Brian Abrahams

Thanks really helpful. that's Yes, Srinivas.

Operator

proceed your Our from question. with with line Judah Suisse. Frommer next of the comes question Please Credit

Judah Frommer

little landscape And treatment the leverage probably Can Change is to a of in this team dosed a the mental like in this move question, the more infrastructure couple any location. or effectively how it as where you in here talk seem are we'll for continues need patients kind the doing some that a and treatment I maybe does of And narratives companies about thanks of need want more reinvent of level as that hi, kind through existing that compounds landscape maybe think treatment on change of real a is health I clinic? are the to kind psychedelics. taking a assuming terms industry. think bit It bit space looking high estate to are developing with space if about evolve. here? Yes, there there in your you thought

Srinivas Rao

I'll that. of Florian heart let Yes, a take

Florian Brand

Yes. Thanks. thinking around to that. Happy to our

executing you now. trials. are J&J the existing building think DNA. on provide leverage summarized, what that's we the how is So And really existed we're pre infrastructure approvals auto we to administer out and we and inpatients certainly in also focused focused. is the right correctly treatments. currently sponsor the were of that's that that R&D our terms intend from It's And And doing or to J&J

be key to in our they're allude on terms of as intend the Srini development how also existing the the kind treatment, I to primarily and or well and us to duration of the kind way development in therapeutics of optimizing pipelines, the pointed what in treatment ecosystem through observe drug all we So its here fit therapies closely duration focus the for of in of of duration general and entirety. the is that by and optimize. to execution to tuning come certainly think time therapist, in infrastructure as out, a already second. leverage the site, In especially involved of this the in like digital But

So into reach and on of here to really Maybe slotting existing things the into kind you for patients add, an thoughtful And possible have to existing especially things as optimize many infrastructure. a as infrastructure in the [X:XX:XX] to Srini, some way. scale really

Srinivas Rao

Yes, think upon mean, the right. you I I hit points, main

therapists, the question for real mentioned it's of are times to the particularly been train, of players So that require other scalability. is there cetera. et one And those limits by cetera, that compounds can number et a number that

both psychedelic with mimics is create approach entire to ketamine. DMT effect that the an in the a So program profile program, salvinorin some way the overall of S

point. something XX and in lift So that action, lasts infrastructure, really over psychedelic less With XXXX a a J&J our really us such traditional heavy that this clinics an the of we have having at range, is that hour, minute to the leverage I targeting to sort short allows that know, duration has than of sitter this has potentially effect you of they ketamine is context. we're and require the believe S XX don't it hypothesis a

the S ketamine. find there's relatively sitter, But we'll real no enough. you if course, of out Of certainly soon context will, in

there therapy course both the do and the patient post is well. utility that we supporting believe requires that of pre as effects I and psychedelic mentioned So and as

access If with into beneficial. get baseline provide hardware, and And therapeutic didn't is for we therapy, you which which aspects, I but to provide hardware go you will, to guides. certainly is the standardized Godspeed actually think will a that digital cyber, a if the be will is it. work therapist therapy have going level and of digital What quite our

the mean, is with the their you very kind during their drive you things to you the mindset. I minds really know, effect, and So, get discussion, here idea minds you patient know, suggestible the the are the way to folks that where effect. appropriate read psychedelic where into the of can appropriate know, go these psychedelic prior

So beneficial. relaxing may the patient be

play again, an potentially hardware going cyber to hypothesis efficacy the therapeutics. where important is Ultimately, improve role. with is safety that's and you that So can digital

So that therapeutics, this is of hardware course, based for will of to us. based but research therapeutics, this an feedback area digital is with active digital going be something

Judah Frommer

terms to a that strategies I helpful, dilutive on of as And Pharma? pursuing the that That's of their Is tied is and say, more comment kind there we a specifically kind up tied validating tied thanks. additional is comment? to it something of maybe on general in follow heard bit Big more then a collaboration just it PCN-XXX? of Kind psychedelics to think color approach quick Greg little financings Otsuka non a

Florian Brand

to exuberant partnership validation value. our Sure, I I think guess, from ability of the indicates, perspective our capture

as so very nevertheless therapies, and Srini dialogue the we So we here, to with but in very advantage just want avenue strategic a get we we will have especially think relevant are also potential we course, we especially we success, enabling that the that kind entrepreneurial potential strong that of to assisted alluded avenue, of also agreements that a competitive enter and it, broad capture he given meaning interest generally here, set we and for as the while, been comes potentially Greg generated. one that something as to, that approval, the that compounds for and the we partners. technologies out, strong we for more of our pointed psychedelic mentioned, when and from have optimized it this strategic also players. continue one open on to other It's intend, we to part into our executing all strategy of build value have March demonstrated be That's

value. thank basis case Great, ensure we by always you. your So develop to a case it shareholder on we'll for optimize

Operator

comes Our of Esther your with the Please from question proceed question. next Berenberg. line Hong with

Esther Hong

congratulations and morning, good all Hi, progress. the on

on dose I dissociative depends pretty or wanted PCN-XXX clear follow Is So this to TRD? it Regarding And of. may in who strengthen who question, I've lack dissociative be up. case, been effects, ketamine it is in to Thanks. Or about for more very patients susceptible a high doses? got or effects? that then potential there first have any difference ask

Srinivas Rao

something including looking interesting looking is answer of as of terms aspects. to as don't really short the well know I that patient more into the aspects into, we avenues Obviously, that a question. be I have that's Yes, some we're subsets. of couple we the think really it's metabolomic digital in mean, different of a some

focused that's dose, that be something on with is to if So great honest interest, right we're now, of you.

Esther Hong

safety used etifoxine non generalized from deuterated is France, the its deuterated it. speak then where details history paradigm additional of any And got specifically, using disorder. more GRX-XXX ask anxiety in use in etifoxine the it wanted France? about in you for to treatment the profile about Okay, Can and Thanks.

Srinivas Rao

Yes, absolutely.

old a obviously is this really So approval.

pretty in XXs, of So people benzodiazepine and kind and then profile a drunk this the if was in the as the there approvals of XXs, efficacy. came of was different. you nothing time reciprocal early in quite approved up sort it a viewed At France, with any was major some his that of small sort will, [X:XX:XX]. obvious when but of it the this other XXXX, feeling territories. And that out, in and and attributed were was late and it benzodiazepines But territories, heyday was

something quite populations, the that adverse there was years amount it and limited SSRIs, compared Very to the been looking tolerated. compounds favorable. the to certainly, about XX terms France, compared certainly has I is even a well in compared reported in a to mean, I particularly database safety other the effects, was compounds. lot [ph] exposures, benzo there's cetera, a and against used think So there vulnerable was of was very overall compound And ago was million And, the publication clean patient from safety that's This bias at effects of to very profile sold was elderly, in spoke et bat. that the use. know, right where couple off a you safety. significant

suggesting data any issues kind there's no Specifically, or this dependence compound. addictive properties with that of

Esther Hong

Thanks. Got it.

Operator

Aegis line Our Nathan Please of your comes the Capital. from question. with question Weinstein with next proceed

Nathan Weinstein

everyone my much morning, thanks and taking for question. so Good

has a range you [ph], just when Just a for the OUD pipeline uses the quick KUR-XXX, one consider that of traditional beyond compound broader had? on the given indication set

Srinivas Rao

question. good a that's Yes,

later. So of disorder treatment view And to you know, as [X:XX:XX] of acute use opioid acute the study that it situations, in duration other tend a it's use taking particularly a suggested that pain. with year prescription interesting, know, opioid many done kind for words, short still is spectrum. with study a And you we're was a in sectional cross an large opioid it, a that a opioid if there X% patients was took received that starts opioid, I disorder, they

kind that years. has really things over for need But terrifying. of So course opioids. traditional subsequent there a a a the kind And of that's obviously, regardless, significantly have is down of better profile a compound clamped tolerability than

treatment that's used and a places, for this used, and the an analgesia use to this at, way require that it that publications, individuals of particularly look as you it's like at boards, than that mitigate well treatment acutely And disorder. So, point, withdrawal the non but also the it as used and Reddit is really your opioid to those opioid more [X:XX:XX] spectrum all to some with be were, something of going as pain, both a tolerate again, there's other is compounds can't is we're as symptoms. scheduled is currently if where pain, compound. to the something And investigating basically that looking from right? chronically we're So,

is compound. on develop spectrum we this focusing what that as So we're

Nathan Weinstein

the follow for one obviously, or the if foresee you just the programs different whether programs been multitude had the of in drugs being of the and so beautiful about And curious the of a so API's one it just substance things up any procurement a thanks. of future? different logistical challenge ties Great,

Srinivas Rao

you there a I that's certainly that have specific purified [X:XX:XX]. are challenge. Ibogaine are I extracts know logistical or synthetic, no deuterated mean, semi synthetic there mean, been and lot that of three and

products. have supply for those We agreements good

it issue it hasn't anticipate and issue. being been we don't an So really an

you minimize reasons, like we'd plants impacts. that's from for amount of general, coming a of range are We in stuff the to environmental know, including

will be future that alternative discussion. the are that at for a routes substance, something to looking producing but drug we So that's

Nathan Weinstein

so Thanks much. Great.

Operator

the further no questions call for I'd hand like queue. management back to closing are to There in remarks. the

Greg Weaver

where our you, and where the come. successful everyone, the like the today. forward entire for very we brought would dialing and week. for everyone, what to all us questions and Thanks are all, that times all thank you to investors Very Thank thank that the have and in today exciting to here And for Great, with you also we team future, you. for share and looking we're us. I is that yet

Operator

your this gentlemen, you Thank conclude teleconference. does Ladies and today's participation. for

a disconnect this time may wonderful at lines your day. have You and

Atai Life Sciences (ATAI) 16 Aug 212021 Q2 Earnings call transcript